Alzamend Neuro Inc Net Assets
Alzamend Neuro Inc net assets. Based on the latest financial reports, Alzamend Neuro Inc (ALZN) has net assets worth $5.80 Million USD as of July 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.54 Million) and total liabilities ($2.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Alzamend Neuro Inc to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.80 Million |
| % of Total Assets | 67.93% |
| Annual Growth Rate | N/A |
| 5-Year Change | -94.51% |
| 10-Year Change | N/A |
| Growth Volatility | 236.25 |
Net Assets of Alzamend Neuro Inc (2016–2026)
Net assets of Alzamend Neuro Inc from 2016 to 2026. This chart illustrates how Alzamend Neuro Inc's net assets have evolved over time, based on quarterly financial data. See Alzamend Neuro Inc balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Alzamend Neuro Inc (2016–2026)
The table below shows the annual net assets of Alzamend Neuro Inc from 2016 to 2026. For live market cap and overall valuation, see how much is Alzamend Neuro Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2026-04-30 | $733.21K | -81.52% |
| 2025-04-30 | $3.97 Million | +252.97% |
| 2024-04-30 | $-2.59 Million | -185.18% |
| 2023-04-30 | $3.05 Million | -77.19% |
| 2022-04-30 | $13.35 Million | +563.28% |
| 2021-04-30 | $2.01 Million | +144.97% |
| 2020-04-30 | $821.71K | +159.28% |
| 2019-04-30 | $316.92K | -86.34% |
| 2018-04-30 | $2.32 Million | +496.51% |
| 2017-04-30 | $-584.93K | -551720.75% |
| 2016-04-30 | $-106.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alzamend Neuro Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6729606700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Alzamend Neuro Inc Net Assets Breakdown (April 2026)
Alzamend Neuro Inc net assets breakdown by equity component as of April 2026.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $425.00 | 0.06% |
| Other Components | $68.04 Million | 9279.79% |
| Total Equity | $733.21K | 100.00% |
Alzamend Neuro Inc Competitors by Market Cap
The table below lists competitors of Alzamend Neuro Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Schroders Investment Trusts - Schroder Asian Total Return Investment Company plc
LSE:ATR
|
$7.05 Million |
|
Fidelity Emerging Markets Ord
LSE:FEML
|
$7.05 Million |
|
MSCM Holdings Bhd
KLSE:0041
|
$7.06 Million |
|
Skyline Investment S.A.
WAR:SKL
|
$7.06 Million |
|
FUXING CHINA GRP SD 5
F:3FU1
|
$7.04 Million |
|
JX Luxventure Limited
NASDAQ:JXG
|
$7.04 Million |
|
La Savonnerie de Nyons SA
PA:MLSDN
|
$7.04 Million |
|
Bt Brands Inc
NASDAQ:BTBD
|
$7.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alzamend Neuro Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 3,968,222 to 733,211, a change of -3,235,011 (-81.5%).
- Net loss of 8,772,382 reduced equity.
- New share issuances of 4,829,844 increased equity.
- Other factors increased equity by 707,527.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.77 Million | -1196.43% |
| Share Issuances | $4.83 Million | +658.72% |
| Other Changes | $707.53K | +96.5% |
| Total Change | $- | -81.52% |
Book Value vs Market Value Analysis
This analysis compares Alzamend Neuro Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-04-30 | $0.00 | $1.46 | x |
| 2017-04-30 | $-27.42 | $1.46 | x |
| 2018-04-30 | $68.98 | $1.46 | x |
| 2019-04-30 | $7.27 | $1.46 | x |
| 2020-04-30 | $15.57 | $1.46 | x |
| 2021-04-30 | $37.40 | $1.46 | x |
| 2022-04-30 | $202.30 | $1.46 | x |
| 2023-04-30 | $42.16 | $1.46 | x |
| 2024-04-30 | $-34.51 | $1.46 | x |
| 2025-04-30 | $8.80 | $1.46 | x |
| 2026-04-30 | $0.22 | $1.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alzamend Neuro Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1196.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.84x
- Recent ROE (-1196.43%) is below the historical average (-386.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-69.45K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.51 Million |
| 2018 | -40.18% | 0.00% | 0.00x | 1.04x | $-1.16 Million |
| 2019 | -1534.32% | 0.00% | 0.00x | 4.74x | $-4.89 Million |
| 2020 | -535.02% | 0.00% | 0.00x | 2.21x | $-4.48 Million |
| 2021 | -250.71% | 0.00% | 0.00x | 1.45x | $-5.25 Million |
| 2022 | -92.59% | 0.00% | 0.00x | 1.09x | $-13.70 Million |
| 2023 | -488.53% | 0.00% | 0.00x | 1.94x | $-15.18 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.69 Million |
| 2025 | -113.78% | 0.00% | 0.00x | 1.16x | $-4.91 Million |
| 2026 | -1196.43% | 0.00% | 0.00x | 2.84x | $-8.85 Million |
Industry Comparison
This section compares Alzamend Neuro Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alzamend Neuro Inc (ALZN) | $5.80 Million | 0.00% | 0.47x | $7.05 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, … Read more